Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Neuroendocrine Tumor | Research article

Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients

Authors: Kiwoon Baeg, Cynthia Harris, Monica S. Naparst, Eugene Ahn, Sahityasri Thapi, Jacob Martin, Sheila Rustgi, Grace Mhango, Juan Wisnivesky, Michelle Kang Kim

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Medical centers with varying levels of expertise treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which are relatively rare tumors. This study assesses the impact of center volume on GEP-NET treatment outcomes.

Methods

We used the Surveillance, Epidemiology, and End Results (SEER) registry linked to Medicare claims data. The data includes patients diagnosed between 1995 and 2010 who had no health maintenance organization (HMO) coverage, participated in Medicare parts A and B, were older than 65 at diagnosis, had tumor differentiation information, and had no secondary cancer. We identified medical centers at which patients received GEP-NET treatment (surgery, chemotherapy, somatostatin analogues, or radiation therapy) using Medicare claims data. Center volume was divided into 3 tiers – low, medium, and high – based on the number of unique GEP-NET patients treated by a medical center over 2 years. We used Kaplan-Meier curves and Cox regression to assess the association between volume and disease-specific survival.

Results

We identified 899 GEP-NET patients, of whom 37, 45, and 18% received treatment at low, medium volume, and high-volume centers, respectively. Median disease-specific survival for patients at low and medium tiers were 1.4 years and 5.3 years, respectively, but was not reached for patients at high volume centers. Results showed that patients treated at high volume centers had better survival than those treated in low volume centers (HR: 0.63, 95% CI: 0.4–0.9), but showed no difference in outcomes between medium and high-volume centers.

Conclusions

Our results suggest that for these increasingly common tumors, referral to a tertiary care center may be indicated. Physicians caring for GEP-NET patients should consider early referral to high volume centers.
Literature
1.
go back to reference Öberg K. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(7):72–80.CrossRef Öberg K. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(7):72–80.CrossRef
2.
go back to reference Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRef Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRef
3.
go back to reference Fraenkel M, Kim M, Faggiano A, De Herder W, Valk G, On behalf of the knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–63.CrossRef Fraenkel M, Kim M, Faggiano A, De Herder W, Valk G, On behalf of the knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–63.CrossRef
4.
go back to reference Modlin IM, Oberg K, Chung DC, Jensen RT, De Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.CrossRef Modlin IM, Oberg K, Chung DC, Jensen RT, De Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.CrossRef
5.
go back to reference Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin. 2011;40(1):1–18.CrossRef Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin. 2011;40(1):1–18.CrossRef
6.
go back to reference Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diab Endocrinol. 2018;4(1):16.CrossRef Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diab Endocrinol. 2018;4(1):16.CrossRef
7.
go back to reference Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, De Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors. Neuroendocrinology. 2004;80:394–424.CrossRef Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, De Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors. Neuroendocrinology. 2004;80:394–424.CrossRef
8.
go back to reference Nanets Kunz PL, Reidy-Lagunes D, Anthony LB. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.CrossRef Nanets Kunz PL, Reidy-Lagunes D, Anthony LB. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.CrossRef
9.
go back to reference Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for Gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–24.CrossRef Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for Gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–24.CrossRef
10.
go back to reference Schrag D, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB. Influence of hospital procedure volume on outcomes following surgery for colon cancer. J Am Med Assoc. 2000;284(23):3028–35.CrossRef Schrag D, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB. Influence of hospital procedure volume on outcomes following surgery for colon cancer. J Am Med Assoc. 2000;284(23):3028–35.CrossRef
11.
go back to reference Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18:2327–40.CrossRef Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18:2327–40.CrossRef
12.
go back to reference Begg CB, Cramer L, Hoskins W, Brennan M. Impact of hospital volume on operative mortality for major cancer surgery. Jama. 1998;280(20):1747–51.CrossRef Begg CB, Cramer L, Hoskins W, Brennan M. Impact of hospital volume on operative mortality for major cancer surgery. Jama. 1998;280(20):1747–51.CrossRef
13.
go back to reference SEER Research Data 1973–2015 -- ASCII Text Data. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973–2015), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. SEER Research Data 1973–2015 -- ASCII Text Data. Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) Research Data (1973–2015), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.
14.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRef
15.
go back to reference Birkmeyer JD, Siewers AE, Finlayson EV. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–37.CrossRef Birkmeyer JD, Siewers AE, Finlayson EV. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–37.CrossRef
16.
go back to reference Pillai RK, Jayasree K. Rare cancers: challenges & issues. Indian J Med Res. 2017;145(1):17–27.CrossRef Pillai RK, Jayasree K. Rare cancers: challenges & issues. Indian J Med Res. 2017;145(1):17–27.CrossRef
17.
go back to reference Chen AY, Pavluck A, Halpern M, Ward E. Impact of treating facilities’ volume on survival for early-stage laryngeal cancer. J Sci Specialties Head Neck. 2009;31:1137–43.CrossRef Chen AY, Pavluck A, Halpern M, Ward E. Impact of treating facilities’ volume on survival for early-stage laryngeal cancer. J Sci Specialties Head Neck. 2009;31:1137–43.CrossRef
Metadata
Title
Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients
Authors
Kiwoon Baeg
Cynthia Harris
Monica S. Naparst
Eugene Ahn
Sahityasri Thapi
Jacob Martin
Sheila Rustgi
Grace Mhango
Juan Wisnivesky
Michelle Kang Kim
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07868-8

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine